Capital Expenditure towards Upgradation/Improvement of our existing Manufacturing Facilities -24.427cr

Capital Expenditure towards Construction of a Storage Facility -36.199cr

Pre-payment/Repayment of outstanding Secured Loans -25.98cr

Product Registrations in other countries -26.088cr

Funding our Working Capital Requirements -112.5cr

i.Capital Expenditure towards Upgradation/Improvement of our existing Manufacturing Facilities

ii.Capital Expenditure towards Construction of a Storage Facility

iii.Pre-payment/Repayment of outstanding Secured Loans

iv.Product Registrations in other countries

v.Funding our Working Capital Requirements

andvi.General Corporate Purpose.

Revenue and PAT growth of 38% and 25% respectively indicate solid business performance.

ROE of 55.25% and ROCE of 27.83% reflect efficient use of capital.

Covers multiple pharmaceutical categories, reducing dependency on a single product line.

Sanand facility in Gujarat offers logistical and operational advantages.

Combination of loan license manufacturing and brand marketing enables flexible expansion.

Debt-to-equity ratio of 0.96 shows moderate leverage risk.

Own-brand marketing is still small with only 2 clients abroad.

Over-reliance on loan license clients can affect margins if contracts shift.

smaller market capitalization (~₹103 Cr) means higher volatility and lower liquidity post-listing.

Lack of analyst recommendations makes valuation and growth projections uncertain.